An observational study in Primary Hyperparathyroidism and Primary Hyperparathyroidism Due to Adenoma, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Central Hospital, Nancy, France · Observational
Primary hyperparathyroidism is a disorder of calcium and phosphorus metabolism linked to dysfunction of one or more parathyroid glands. The latest recommendations from the American Association of Endocrine Surgeons (7) consider the presence of hypertension as an argument for proposing the removal of a parathyroid adenoma in the context of primary hyperparathyroidism. The renin-angiotensin-aldosterone system is involved in regulating blood pressure.
The main objective of this study is to assess aldosterone level in patients with primary hyperparathyroidism before surgery and its variation in the year following surgery for parathyroid disease.
Secondary objectives are to assess aldosterone variations after surgery at 3 months
Assess antihypertensive treatment according to the WHO-DDD classification before and after surgery Compare aldosterone levels in the 'primary hyperparathyroidism' group with a control group of patients from the general population (using the STANISLAS cohort).
Primary hyperparathyroidism is a disorder of calcium and phosphorus metabolism linked to dysfunction of one or more parathyroid glands, without any underlying chronic kidney disease. The disease manifests itself in its classic forms as elevated blood calcium, parathyroid hormone and calcium levels. It has an impact on bone mineralisation, the presence of kidney stones, glucose metabolism (1)(2) and cardiovascular function (3)(4)(5).
A Scottish study published in 2023, based on a robust medical information system enabling prospective follow-up, showed an overall prevalence of primary hyperparathyroidism between 2007 and 2018 of 0.84%, which was much higher in women (1.18%) than in men (0.48%) (6) The latest recommendations from the American Association of Endocrine Surgeons (7) consider the presence of hypertension as an argument for proposing the removal of a parathyroid adenoma in the context of primary hyperparathyroidism: 'Parathyroidectomy may be offered to surgical candidates with cardiovascular disease who might benefit from mitigation of potential cardiovascular sequelae other than hypertension.' There appears to be an association between hypertension and primary hyperparathyroidism (4)(5). Its mechanism is currently poorly understood and little described. Using the keywords 'hyperaldosteronism' AND 'hyperparathyroidism', we found only one case report (in Spanish) and one article, but these focused more on patients already suffering from primary hyperaldosteronism (8)(9).
The renin-angiotensin-aldosterone system is involved in regulating blood pressure.
This is why we systematically measure aldosterone and renin preoperatively and at three postoperative points following surgery for primary hyperparathyroidism.
This is a retrospective study including among 400 patients with primary hyperparathyroidism. Allt his patients underwent parathyroidectomy.
Inclusion critera : patients with primary hyperparathyroidism, age>18 years Exclusion criteria : patients with hyperparathyroidism and renal insuffisency Pregant women, patients \< 18 years. All patients underwent blood tests including PTH, calcium, aldosterone and renin levels before surgery and 3 months, 6 months and 12 months after surgery.
The number and type of antihypertensive treatments were systematically recorded before and 3 months after surgery.
In a second step, the aldosterone levels of patients with primary hyperparathyroidism will be compared with a cohort of patients from the general population: the STNISLAS cohort, and with a cohort of patients with cardiovascular disease. This will enable to identify whether aldosterone levels in the population of patients with primary hyperparathyroidism differ from those in the general population.
The Main objective is to assess the role of phosphorus-calcium metabolism on the renin-angiotensin system in patients with primary hyperparathyroidism (PHPT)
The Secondary objectives are :
8) To compare the renin-angiotensin system (plasma aldosterone and renin levels) in patients with PHPT versus patients with cardiovascular disease (REMI cohort)
104 studies on the registry are indexed under Hyperparathyroidism, Primary; 23 are open to participants now.
This study's planned enrollment of 400 is above the median of 130 across 40 observational studies indexed under Hyperparathyroidism, Primary.
Browse Hyperparathyroidism, Primary studies →Central Hospital, Nancy, France is the lead sponsor of 798 studies on the registry; 186 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with primary hyperparathyroidism, without renal insufficiency , candidate to parathyroid surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
age\< 18 years patients with renal insufficiency (CKDEpi \<60ml/mn) pregant women
-
Patients with primary hyperparathyroidism who are candidates for surgery. All patients underwent biological testing for parathyroid hormone, calcium, aldosterone, renin and renal function. Their blood pressure was measured five times during the pre-operative consultation and after surgery. Their antihypertensive treatments were collected prior to surgery and after.
Aldosteron variation before and after surgery
Variation of aldosteron level between the time before surgery and after surgery at 3 points : 3,6 and 12 months after surgery
Time frame: from enrollment to 12 months after surgery
Plasma Parathormon levels
Preoperative and postoperative Plasma parathormone levels
Time frame: 3 months before surgery to 12 months after surgery The measure is done at 3,6 and 12 months after surgery
Plasma Calcium and Phosphorus levels
Preoperative and postoperative Plasma calcium and phosphorus levels
Time frame: 3 months before surgery to 12 months after surgery The measure is done at 3,6 and 12 months after surgery
Plasma renin levels
Preoperative and postoperative Plasma renin levels
Time frame: 3 months before surgery to 12 months after surgery The measure is done at 3,6 and 12 months after surgery
type and number of antihypertensive medications
Preoperative and postoperative type and number of antihypertensive medications : the number, the type and the dosage of anti-hypertensive drugs is collected before and 3 months after surgery
Time frame: from 3 months before surgery to 3 months after
WHO_DDD classification
Using the WHO\_DDD classification , a score of anti-hypertensive medication is calculated before and after surgery for each patient.
Time frame: from 3 months before surgery to 3 months after
Systolic and diastolic blood pressure (SBP and DBP)
Preoperative and postoperative SBP and DBP value in mmHg are systematically measured 3 months before and 3 months after surgery.
Time frame: from 3 months before surgery to 3 months after
Preoperative glomerular filtration rate (GFR)
Preoperative glomerular filtration rate (GFR) is measured before surgery. Patients with renal insufficiency are excluded.
Time frame: 3 months before surgery.
Preoperative 25 OH vitD
Plasma of 25OH vitamin D before surgery
Time frame: 3 months before surgery
Preoperative 24h calciuria
24h calciuria 3 months before surgery
Time frame: 3 months before surgery
Kidney stones
Presence of kidney stones on ultrasound or abdominal CT scan prior to parathyroid surgery
Time frame: 3 months before surgery
femoral T score
Femoral T-score on preoperative bone densitometry
Time frame: 3 months before surgery
Plan to share: Undecided
Start is estimated for Feb 2026; primary completion for Sep 2026, 7 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperparathyroidism, Primary →
Central Hospital, Nancy, France →